Acute myeloid leukemia (AML) is an aggressive blood cancer caused by a plethora of genetic mutations acquired throughout one’s lifetime. One of these genes, the tumor suppressor gene TP53, plays a crucialRead More…
T-cell receptor-engineered T cells (TCR-T) represent a form of cellular immunotherapy and a subtype of adoptive cell transfer (ACT). It involves the identification and selection of TCR sequences capable of specifically bindingRead More…
In a recent study, researchers from the University of Texas MD Anderson Cancer Center in the United States reported favorable results from a Phase I/II clinical trial involving 37 patients with relapsedRead More…
The use of modified chimeric antigen receptor (CAR) T cells (CAR-T) in immunotherapy has significantly improved the survival rates of pediatric patients with relapsed leukemia. However, these therapies are not as effectiveRead More…
In a recent study, researchers from Stanford University in the United States collected data from previous studies on CAR-T cell therapy to investigate the reactivation of human herpesvirus 6 (HHV-6) in patientsRead More…
In recent years, scientists have harnessed the power of gene editing technology to reprogram immune cells into therapies capable of targeting cancer. However, these immunotherapies are not universally effective across all patientsRead More…
In a recent study, researchers from the University of Illinois Urbana-Champaign in the United States have discovered that CAR-T cell immunotherapy could potentially be a highly effective treatment for solid tumors ifRead More…
In a recent study conducted by researchers from institutions including the MD Anderson Cancer Center at the University of Texas, USA, it has been discovered that the loss of metabolic capacity inRead More…
Immunotherapy strategies aim to utilize the patient’s own immune system cells to eliminate tumor cells. CAR-T cell therapy is an effective treatment for human blood cancers. In France, approximately 35,000 people areRead More…
A small-scale clinical trial suggests that an improved form of CAR-T cell therapy, known as Descartes-08, holds promise for treating myasthenia gravis, an autoimmune neuromuscular disease. The modified CAR-T therapy used inRead More…